Natco Pharma Reports 57% Drop in Q1 Profit, Posting Rs 206.5 Crore Earnings.
Natco Pharma Ltd has reported a significant contraction in its consolidated net profit for the first quarter ended June 2026, with a decline of 57% year-on-year to Rs 206.5 crore, down from Rs 480.3 crore in the same quarter last fiscal year. This downturn is primarily linked to diminished sales of its generic cancer treatment drug, lenalidomide, which substantially impacted overall financial performance. The consolidated revenue from operations also saw a sharp decline, dropping to Rs 735.2 crore from Rs 1,328.9 crore a year ago, indicating substantial challenges within its revenue-generating segments.
The reported figures highlight a contrasting performance in various segments. While revenue from domestic pharmaceutical formulations increased to Rs 136.4 crore from Rs 107 crore year-on-year, this growth was overshadowed by a steep drop in international formulation revenues, which plummeted to Rs 477.1 crore from Rs 1,120.9 crore in the corresponding period of the previous fiscal. Notably, the active pharmaceutical ingredients (API) segment demonstrated resilience, with revenues rising to Rs 66.7 crore from Rs 52.6 crore, albeit this segment remains a smaller contributor to the company’s overall revenue.
Total expenses for the quarter were reduced to Rs 608.8 crore from Rs 818.7 crore, reflecting a strategic effort to manage operating costs amid declining sales. This cost control could mitigate some of the profit erosion; however, it remains to be seen whether these measures can sustain overall profitability in subsequent quarters. The decline in lenalidomide sales is particularly concerning for investors, as the drug has been a significant revenue driver for Natco Pharma.
Moving forward, investors should closely monitor the company’s strategic initiatives aimed at enhancing product portfolio and expanding market presence, especially in international markets where the current performance has been disappointing. The uptick in domestic pharmaceutical formulations and the growth in the API segment may provide some buffer, but the overarching reliance on lenalidomide sales underscores the need for a diversified revenue strategy to promote stability and growth in an increasingly competitive landscape.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)